- Josep Tabernero joins SAB and Julian Blagg elevated to SAB Chair
- Martin Drysdale appointed VP of Drug Discovery
4th August 2020, Cambridge, UK – NeoPhore Limited, a small molecule cancer neoantigen immuno-oncology company, today announces the appointment of Dr Josep Tabernero as member of the Scientific Advisory Board (SAB) and the elevation of Dr Julian Blagg to Chair of the SAB. The strengthening of the scientific team is complemented with the appointment of Dr Martin Drysdale as Vice President (VP) of Drug Discovery. These new additions follow the announcement of Dr Matthew Baker’s appointment as Chief Executive Officer earlier this year.